

Supplementary Table 4. Patient and tumor characteristics according to initial treatment

| Variable | Sorafenib (n=69) | BSC (n=50) | Surgery (n=88) | Non-surgical local treatment (n=231) | P-value |
|---------------------|----------------------------|-----------------------------|--------------------------|---|---------|
| Age | 57 (51-64) | 58 (51-68) | 59 (52-69) | 57 (50-67) | 0.507 |
| ECOG PS | | | | | <0.001 |
| 0-1 | 67 (97.1) | 40 (80.0) | 88 (100.0) | 227 (98.3) | |
| 2-4 | 2 (2.9) | 10 (20.0) | 0 (0.0) | 4 (1.7) | |
| Gender | | | | | 0.318 |
| Female | 5 (7.2) | 7 (14.0) | 15 (17.0) | 28 (12.1) | |
| Male | 64 (92.8) | 43 (86.0) | 73 (83.0) | 203 (87.9) | |
| Child-Pugh class | | | | | <0.001 |
| A | 59 (85.5) | 14 (28.0) | 87 (98.9) | 197 (85.3) | |
| B/C | 10 (14.5) | 36 (72.0) | 1 (1.1) | 34 (14.7) | |
| mALBI grade | | | | | <0.001 |
| 1 | 33 (47.8) | 5 (10.0) | 76 (86.4) | 130 (56.3) | |
| 2a | 21 (30.4) | 7 (14.0) | 11 (12.5) | 52 (22.5) | |
| 2b/3 | 15 (21.7) | 38 (76.0) | 1 (1.1) | 49 (21.2) | |
| AFP (ng/mL) | 2,189.4 (58.3-30,056.0) | 4,915.5 (206.0-60,500.0) | 150.7 (5.6-12,141.4) | 843.2 (29.0-19,852.3) | <0.001 |
| PIVKA-II (mAU/mL) | 8,251.0 (1,477.0-28,589.0) | 39,887.0 (7,343.0-75,000.0) | 5,875.0 (488.0-27,660.5) | 7,159.0 (1,302.0-32,409.0) | <0.001 |
| Tumor size (cm) | 15.0 (13.3-15.0) | 15.0 (13.0-15.0) | 12.0 (9.0-15.0) | 15.0 (9.4-15.0) | <0.001 |
| Vascular invasion | 16 (23.2) | 7 (14.0) | 4 (4.5) | 33 (14.3) | 0.009 |
| Bile duct invasion | 3 (4.3) | 6 (12.0) | 3 (3.4) | 10 (4.3) | 0.165 |
| PVTT classification | | | | | <0.001 |
| Vp0 | 15 (21.7) | 14 (28.0) | 71 (80.7) | 82 (35.5) | |
| Vp1/2 | 7 (10.1) | 3 (6.0) | 9 (10.2) | 46 (19.9) | |
| Vp3/4 | 47 (68.2) | 33 (66.0) | 8 (9.1) | 103 (44.6) | |
| LN metastasis | 25 (36.2) | 10 (20.0) | 3 (3.4) | 40 (17.3) | <0.001 |
| mUICC | | | | | <0.001 |
| II | 0 (0.0) | 3 (6.0) | 51 (58.0) | 30 (13.0) | |
| III | 11 (15.9) | 12 (24.0) | 24 (27.3) | 72 (31.2) | |
| IVA | 23 (33.3) | 17 (34.0) | 6 (6.8) | 88 (38.1) | |
| IVB | 35 (50.7) | 18 (36.0) | 7 (8.0) | 41 (17.7) | |
| BCLC | | | | | <0.001 |
| A-B | 2 (2.9) | 3 (6.0) | 63 (71.6) | 49 (21.2) | |
| C-D | 67 (97.1) | 47 (94.0) | 25 (28.4) | 182 (78.8) | |

Values are presented as patient number (%) or median (interquartile range).

BSC, best supportive care; ECOG PS, Eastern Cooperative Oncology Group performance status; mALBI, modified albumin-bilirubin score; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; PVTT, portal vein tumor thrombosis; LN, lymph node; mUICC, modified International Union Against Cancer; BCLC, Barcelona Clinic Liver Cancer.